The present disclosure relates to systems and methods of using machine learning analysis to stratify the risk of spontaneous preterm birth (SPTB). In some variations, to select informative markers that differentiate SPTB from term deliveries, a processed quantification data of the markers can be subjected to univariate receiver operating characteristic (ROC) curve analysis. A Differential Dependency Network (DDN) can then applied in order to extract co-expression patterns among the markers. In order to assess the complementary values among selected markers and the range of their relevant performance, multivariate linear models can be derived and evaluated using bootstrap resampling.

A method of determining suitability of a pregnant woman to be a candidate for induction of labor can include: obtaining a vaginal fluid sample from a pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determination of suitability for induction of labor to the pregnant woman. When the PAMG-1-antibody complex forms, the pregnant woman is determined to be in a condition that is not suitable for induction of labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the pregnant woman is determined to be in a condition that is suitable to be a candidate for induction of labor because the PAMG-1 is not detected in the vaginal sample.

An immune device for pregnancy diagnosis of the inventive concept includes a sample region for receiving a test sample to be analyzed; a conjugate region connected to the sample region and including an anti-I-hCG antibody conjugated with a probe and an anti-cf hCG antibody conjugated with a probe; a signal detection region connected with the conjugate region, wherein the signal detection region includes a first test line having an anti-I-hCG antibody immobilized to the first test line, a second test line having an anti-cf hCG antibody immobilized to the second test line, and a control line; and a wicking region located downstream of the signal detection region, wherein the wicking region absorbs the test sample for which a signal detection reaction has terminated.

Cells transfected with DNA sequences encoding for a PreImplantation Factor (PIF) or a PIF and one or more fusion tag(s) are disclosed. Also disclosed are DNA sequences encoding for synthetic PIFs, a PIF fusion peptide made of a PIF and one or more fusion tags, methods of treatment using the transfected cells that express a PIF, an R-I-K-P peptide, compositions containing the R-I-K-P peptide, and methods of identifying a compound that binds to an active site of an WX.sub.1WX.sub.2X.sub.3X.sub.4REWFX.sub.5X.sub.6X.sub.7W receptor, wherein each X can be any amino acid.

A method of making a noninvasive molecular control and analysis is described. The method of making the noninvasive molecular control includes, predetermining a positive control for a condition of interest, selecting a cell line with a control marker for the condition of interest, amplifying release of cfDNA from the selected cell line, isolating the released cfDNA from the selected cell line, quantifying the control marker from the isolated cfDNA, determining a volume of the control marker for addition to an isolated control plasma, isolating the control plasma from a control sample, treating the isolated control plasma with a control stabilizer, determining a volume of the control plasma to add to the volume of control marker, combining the volume of the control marker with the isolated control plasma, and analyzing a sample against the noninvasive molecular control to determine the presence or absence of a condition of interest.

Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

The present invention relates to a diagnosis method of liver cancer using mass spectrometry of -fetoprotein derived glycopeptide. Particularly, according to the AFP glycopeptide analysis method of the invention, fucosylation rate of the glycopeptide having the sequence composed of Val-Asn-Phe-Thr-Glu-Ile-Gln-Lys is analyzed to diagnose liver cancer in the early developmental grade. In particular, fucosylation rate is higher in the liver cancer patients than in other liver disease patients, so that the comparison of the fucosylation rate can be useful to diagnose or distinguish liver cancer from other liver diseases in the early HCC patients.

A method of determining risk of preterm labor in an asymptomatic pregnant woman can include: obtaining a vaginal fluid sample from an asymptomatic pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determined risk to the pregnant woman. When the PAMG-1-antibody complex forms, the asymptomatic pregnant woman is determined to be susceptible to preterm labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the asymptomatic pregnant woman is determined to be not susceptible to preterm labor because the PAMG-1 is not detected in the vaginal sample.

Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

Provided is a method for identifying and treating a pregnancy devoid of uterine fetal or embryonic tissue in a subject by determining a concentration of alpha-fetoprotein (AFP) in a specimen evacuated from the uterus of the subject; comparing the concentration of AFP to a reference value; wherein when the AFP concentration in the specimen evacuated from the uterus is below that of a reference value, absence of uterine fetal or embryonic tissue is indicated. Also provided is a method for identifying and treating a presence of fetal or embryonic tissue in a location of a subject other than the uterus by determining a concentration of AFP in a non-uterine specimen obtained from the subject; comparing the concentration of AFP in the specimen to a reference value; wherein when the AFP concentration in the specimen is above that of a reference value, presence of fetal or embryonic tissue is indicated.